This document provides an extensive list of over 100 categories of due diligence documents and information requested for the acquisition of a target company. It includes requests for organizational charts, corporate records, financial statements, tax filings, contracts, intellectual property information, real estate documents, employee and labor records, benefits information, and other operational and legal materials. The level of detail requested is intended to provide thorough information on all financial, legal, and operational aspects of the target company to evaluate it as an acquisition.
This document provides guidance on planning preclinical testing for medical device development. It outlines key aspects to consider, including material selection, manufacturing methods, biocompatibility testing, study design, packaging and sterilization validation. Manufacturers are advised to review industry standards, evaluate all potential impacts to safety and performance, and plan timelines for all required activities and documentation. Attention to these details at the preclinical stage will help ensure a successful medical device design validation process.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
This document summarizes a presentation on future compliance requirements related to medical devices. It discusses changes coming in how medical devices are named (GMDN), tracked (UDI), and have data captured (AIDC/GS1 coding). The Global Medical Device Nomenclature (GMDN) will standardize device names. Unique Device Identification (UDI) will assign each device a unique identifier tracked in a public database. Automatic identification like GS1 coding will help interface equipment and data. Hospitals should prepare by understanding these changes to integrate new identification standards.
12 Steps for Medical Device UDI Submissions to the FDA GUDIDJoe Hage
UDI regulations kick in for Implantables and Class II devices in 2015.
Reed Tech subject matter expert Gary Saner is my go-to on this subject. He covered:
• Requirements of a GUDID submission system
• Process steps in selecting/launching a GUDID system and making submissions
• Data Fields – including those that are problematic
• Data Cleaning, Harmonization, and Validation tips
• Update on FDA’s changing GUDID guidance, e.g., convenience kits and implants
• Notes in setting up a FDA GUDID account
RELEVANT FOR:
• UDI Team Leaders/Members
• Regulatory Directors/Managers/Staff
• Manufacturing, Operations, and Supply Chain Logistics Personnel
• UDI IT Support Personnel
• Compliance Officers
• Distributors with UDI Submission Responsibilities
Video at http://medgroup.biz/UDI-in-2015
Safety and Pharmacovigilance System: Oracle Argus Safety SuitePerficient
Oracle's Argus Safety is a comprehensive pharmacovigilance platform designed to help life sciences companies ensure global regulatory compliance, enable faster safety decisions through data insights, and integrate safety and risk management functions. With Argus Safety, companies can manage regulatory reporting requirements, obtain visibility into reporting metrics and compliance, and leverage automation and advanced functionality to maximize case processing efficiency and data access for timely review. Argus Safety also provides integrated risk management capabilities and can be seamlessly connected to signal detection systems to proactively manage product safety.
The document discusses medical device regulations from various agencies like the FDA and EU, which classify devices based on risk into Classes I to III. It also covers quality management systems like ISO 13485 that are important for product development and design controls. The key elements of design control as required by regulatory agencies are also summarized, including design planning, input, output, review, verification, and validation.
The US FDA regulates medical devices to ensure they are safe and effective. There are three classes of medical devices with increasing regulatory controls based on risk. Class I devices have general controls, Class II devices have general and special controls, and Class III devices require premarket approval. To market a device in the US, manufacturers must classify their device, submit the appropriate premarket notification or application, and complete an establishment registration and device listing. The FDA reviews submissions to ensure devices reasonably assure safety and effectiveness.
This document provides guidance on planning preclinical testing for medical device development. It outlines key aspects to consider, including material selection, manufacturing methods, biocompatibility testing, study design, packaging and sterilization validation. Manufacturers are advised to review industry standards, evaluate all potential impacts to safety and performance, and plan timelines for all required activities and documentation. Attention to these details at the preclinical stage will help ensure a successful medical device design validation process.
Medical Device Regulation (MDR) overview for Technion, May 25, 2021Levi Shapiro
On May 26, 2021, the EU introduced the most sweeping changes to the Medical Device legal framework since the mid 90's. Ulf Grundmann, Senior Partner, King & Spalding (Frankfurt), reviews some of these regulatory changes, from the perspective of medical device innovators. The presentation includes Scope and Definitions, Classification and Conformity Assessment, Placing a Device on the EU Market, UDI and EUDAMED, Supply Chain Obligations, PMS and Vigilance
This document summarizes a presentation on future compliance requirements related to medical devices. It discusses changes coming in how medical devices are named (GMDN), tracked (UDI), and have data captured (AIDC/GS1 coding). The Global Medical Device Nomenclature (GMDN) will standardize device names. Unique Device Identification (UDI) will assign each device a unique identifier tracked in a public database. Automatic identification like GS1 coding will help interface equipment and data. Hospitals should prepare by understanding these changes to integrate new identification standards.
12 Steps for Medical Device UDI Submissions to the FDA GUDIDJoe Hage
UDI regulations kick in for Implantables and Class II devices in 2015.
Reed Tech subject matter expert Gary Saner is my go-to on this subject. He covered:
• Requirements of a GUDID submission system
• Process steps in selecting/launching a GUDID system and making submissions
• Data Fields – including those that are problematic
• Data Cleaning, Harmonization, and Validation tips
• Update on FDA’s changing GUDID guidance, e.g., convenience kits and implants
• Notes in setting up a FDA GUDID account
RELEVANT FOR:
• UDI Team Leaders/Members
• Regulatory Directors/Managers/Staff
• Manufacturing, Operations, and Supply Chain Logistics Personnel
• UDI IT Support Personnel
• Compliance Officers
• Distributors with UDI Submission Responsibilities
Video at http://medgroup.biz/UDI-in-2015
Safety and Pharmacovigilance System: Oracle Argus Safety SuitePerficient
Oracle's Argus Safety is a comprehensive pharmacovigilance platform designed to help life sciences companies ensure global regulatory compliance, enable faster safety decisions through data insights, and integrate safety and risk management functions. With Argus Safety, companies can manage regulatory reporting requirements, obtain visibility into reporting metrics and compliance, and leverage automation and advanced functionality to maximize case processing efficiency and data access for timely review. Argus Safety also provides integrated risk management capabilities and can be seamlessly connected to signal detection systems to proactively manage product safety.
The document discusses medical device regulations from various agencies like the FDA and EU, which classify devices based on risk into Classes I to III. It also covers quality management systems like ISO 13485 that are important for product development and design controls. The key elements of design control as required by regulatory agencies are also summarized, including design planning, input, output, review, verification, and validation.
The US FDA regulates medical devices to ensure they are safe and effective. There are three classes of medical devices with increasing regulatory controls based on risk. Class I devices have general controls, Class II devices have general and special controls, and Class III devices require premarket approval. To market a device in the US, manufacturers must classify their device, submit the appropriate premarket notification or application, and complete an establishment registration and device listing. The FDA reviews submissions to ensure devices reasonably assure safety and effectiveness.
Quality Considerations in Due Diligence for Pharmaceutical TransactionsMichael Swit
The document discusses quality considerations in due diligence for pharmaceutical transactions. It outlines general considerations for due diligence structure and challenges. It emphasizes that quality matters because drugs made in non-compliant facilities can be considered adulterated by the FDA and result in criminal and civil penalties. The document provides examples of problems to look for, including manufacturing, pharmacovigilance, compliance history, FDA inspection history, and audits. It discusses techniques for probing issues, including reviewing FDA correspondence and litigation. Special considerations are outlined for different drug development stages. Helpful charts on diligence issues by stage and analyzing identified issues are presented.
Medical device industry 2014 - A Healthcare Sector AnalysisVikas Soni
Medical Device Industry and its impact on Healthcare Sector of India for FY2014 along with Current Scenario of Global, US, EU and Indian Medical device market.
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Introduction to Oracle Clinical Overview in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
The pharmaceutical industry in Bangladesh has grown significantly since the 1950s and is now the second largest contributor to the country's economy. There are over 230 pharmaceutical companies in Bangladesh that produce around 97% of the drugs used domestically. The industry has grown at a fast pace, with the market size reaching 30 billion taka annually and exports now going to 79 different countries. However, to realize its full potential, the industry still needs more investment in research and development facilities as well as incentives for exporting active pharmaceutical ingredients.
Rules and regulations for medical device registration, forms and fees required, types of medical devices to be registered under CDSCO India.
Indian market overview
India’s medical device regulatory structure
Categories of regulated medical devices in India
No Objection Certificates
Device Registration Certificate applications
Import Licensing
India Authorized Agent selection
Costs and Timelines
Developing Regulatory Issues in India
Difference between fda 21 cfr part 820 and ISO 13485Anil Chaudhari
The document compares FDA 21 CFR Part 820 and ISO 13485 quality management standards. ISO 13485 is an international voluntary standard that specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and services that consistently meet regulatory requirements. In contrast, FDA 21 CFR Part 820 outlines current good manufacturing practice regulations in the US that govern the design, manufacture, and distribution of medical devices to ensure safety and effectiveness. Key differences include ISO 13485 being a global voluntary standard while FDA 21 CFR Part 820 is mandatory for medical device manufacturers selling products in the US.
The UDI system was created, developed and maintained by the device manufacturer based on global device identification standards. Today, it also helps with procurement and reimbursement. The Regulations allow for random inspections of producers’ facilities after devices have been placed on the market.
- The document discusses data integrity, which refers to maintaining accurate and consistent data over its entire lifecycle. This is important for the regulated healthcare industry as quality decisions are based on data.
- The FDA uses the ALCOA criteria (Attributable, Legible, Contemporaneous, Original, Accurate) to define expectations for electronic data. Regulatory agencies now focus heavily on data integrity due to instances of fabricated documents and errors.
- Common data integrity issues found by agencies include non-contemporaneous recording, backdating records, re-running samples until desired results are obtained, and data fabrication. Ensuring data integrity helps prevent regulatory actions like warning letters or import bans against companies.
Macleods Pharmaceuticals is an Indian pharmaceutical company incorporated in 1986 with a global presence in over 80 countries. It has a wide product portfolio across several therapeutic areas and strong manufacturing capabilities. Macleods researches, develops and manufactures generic drugs with a focus on affordable healthcare. It aims to become a leading global pharmaceutical company through innovative therapies and a vertically integrated business model.
505(b)(2) new drug application (NDA) is one of three U.S. Food and Drug Administration (FDA) drug which was created by Hatch-Waxman Amendments of 1984, with 505(b)(2) referring to as a section of the Federal Food, Drug, and Cosmetic Act.
GlaxoSmithKline (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London.
Pfizer is the world's largest pharmaceutical company with revenues of $49.6 billion in 2014. It has over 78,000 employees worldwide and key products include Lipitor, Lyrica, Viagra, and Celebrex. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. Pfizer utilizes a complex global supply chain network involving over 300 suppliers to procure and deliver materials and finished products to customers in over 175 distribution centers worldwide while managing risks such as cargo theft and counterfeiting.
The document defines FDA warning letters and describes the process of FDA inspections that can lead to warning letters. It explains that warning letters notify companies of violations found during inspections and investigations. Companies must promptly correct issues and FDA will check that corrections are adequate. The document also describes different types of warning letters for various regulated industries and how to browse existing warning letters on the FDA website.
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
Introduction Reconciliation and Literature Review and Signal Detection in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
A brief introduction on medical device , how iit is regulated in india,its marketing authorization,classification, notified devices,import of device and registration process, fnctions of medical device department.
Module 01 Introduction To FdA and Quality System RegulationQACATX
The document provides an overview of the history and development of regulations by the U.S. Food and Drug Administration (FDA). It discusses the origins of the FDA in the late 19th/early 20th century in response to concerns about food and drug safety. Major milestones include the 1906 Pure Food and Drug Act, the 1938 Federal Food, Drug, and Cosmetic Act, and the 1976 Medical Device Amendments. The Quality System Regulation of 1996 refined Good Manufacturing Practice standards and emphasized design controls to ensure medical devices and manufacturers meet FDA requirements for safety and effectiveness. The regulation establishes requirements in several areas including management responsibility, design controls, purchasing, corrective actions, and distribution that medical device manufacturers must comply with.
This document is the annual report on Form 10-K filed by iTeos Therapeutics, Inc. with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2021. The report provides information on iTeos' business operations, financial results, subsidiaries, legal proceedings, executive officers, directors and auditors. It also includes iTeos' audited financial statements.
The document discusses Sri Lanka's transition to International Financial Reporting Standards (IFRS). It provides an overview of SLFRS and LKAS accounting standards. It outlines the diagnostic stage for assisting companies transitioning to SLFRS, including the transition date, comparative period, and reporting period. Disclosure requirements under SLFRS are also summarized such as the minimum content required for financial statements and notes.
Quality Considerations in Due Diligence for Pharmaceutical TransactionsMichael Swit
The document discusses quality considerations in due diligence for pharmaceutical transactions. It outlines general considerations for due diligence structure and challenges. It emphasizes that quality matters because drugs made in non-compliant facilities can be considered adulterated by the FDA and result in criminal and civil penalties. The document provides examples of problems to look for, including manufacturing, pharmacovigilance, compliance history, FDA inspection history, and audits. It discusses techniques for probing issues, including reviewing FDA correspondence and litigation. Special considerations are outlined for different drug development stages. Helpful charts on diligence issues by stage and analyzing identified issues are presented.
Medical device industry 2014 - A Healthcare Sector AnalysisVikas Soni
Medical Device Industry and its impact on Healthcare Sector of India for FY2014 along with Current Scenario of Global, US, EU and Indian Medical device market.
Pfizer is a global pharmaceutical company founded in 1849 and headquartered in New York. It produces medicines and vaccines. The document discusses Pfizer's global inventory management strategy, including inventory control techniques like reorder levels and safety stock levels. It also covers Pfizer's focus on efficiency, resilience, agility, quality control, and supply chain best practices and challenges. The presentation was submitted by Milind and team to Prof. Jaison Mathews.
Introduction to Oracle Clinical Overview in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
The pharmaceutical industry in Bangladesh has grown significantly since the 1950s and is now the second largest contributor to the country's economy. There are over 230 pharmaceutical companies in Bangladesh that produce around 97% of the drugs used domestically. The industry has grown at a fast pace, with the market size reaching 30 billion taka annually and exports now going to 79 different countries. However, to realize its full potential, the industry still needs more investment in research and development facilities as well as incentives for exporting active pharmaceutical ingredients.
Rules and regulations for medical device registration, forms and fees required, types of medical devices to be registered under CDSCO India.
Indian market overview
India’s medical device regulatory structure
Categories of regulated medical devices in India
No Objection Certificates
Device Registration Certificate applications
Import Licensing
India Authorized Agent selection
Costs and Timelines
Developing Regulatory Issues in India
Difference between fda 21 cfr part 820 and ISO 13485Anil Chaudhari
The document compares FDA 21 CFR Part 820 and ISO 13485 quality management standards. ISO 13485 is an international voluntary standard that specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and services that consistently meet regulatory requirements. In contrast, FDA 21 CFR Part 820 outlines current good manufacturing practice regulations in the US that govern the design, manufacture, and distribution of medical devices to ensure safety and effectiveness. Key differences include ISO 13485 being a global voluntary standard while FDA 21 CFR Part 820 is mandatory for medical device manufacturers selling products in the US.
The UDI system was created, developed and maintained by the device manufacturer based on global device identification standards. Today, it also helps with procurement and reimbursement. The Regulations allow for random inspections of producers’ facilities after devices have been placed on the market.
- The document discusses data integrity, which refers to maintaining accurate and consistent data over its entire lifecycle. This is important for the regulated healthcare industry as quality decisions are based on data.
- The FDA uses the ALCOA criteria (Attributable, Legible, Contemporaneous, Original, Accurate) to define expectations for electronic data. Regulatory agencies now focus heavily on data integrity due to instances of fabricated documents and errors.
- Common data integrity issues found by agencies include non-contemporaneous recording, backdating records, re-running samples until desired results are obtained, and data fabrication. Ensuring data integrity helps prevent regulatory actions like warning letters or import bans against companies.
Macleods Pharmaceuticals is an Indian pharmaceutical company incorporated in 1986 with a global presence in over 80 countries. It has a wide product portfolio across several therapeutic areas and strong manufacturing capabilities. Macleods researches, develops and manufactures generic drugs with a focus on affordable healthcare. It aims to become a leading global pharmaceutical company through innovative therapies and a vertically integrated business model.
505(b)(2) new drug application (NDA) is one of three U.S. Food and Drug Administration (FDA) drug which was created by Hatch-Waxman Amendments of 1984, with 505(b)(2) referring to as a section of the Federal Food, Drug, and Cosmetic Act.
GlaxoSmithKline (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London.
Pfizer is the world's largest pharmaceutical company with revenues of $49.6 billion in 2014. It has over 78,000 employees worldwide and key products include Lipitor, Lyrica, Viagra, and Celebrex. In India, Pfizer has over 3,000 employees and a manufacturing facility in Thane, Maharashtra. Pfizer utilizes a complex global supply chain network involving over 300 suppliers to procure and deliver materials and finished products to customers in over 175 distribution centers worldwide while managing risks such as cargo theft and counterfeiting.
The document defines FDA warning letters and describes the process of FDA inspections that can lead to warning letters. It explains that warning letters notify companies of violations found during inspections and investigations. Companies must promptly correct issues and FDA will check that corrections are adequate. The document also describes different types of warning letters for various regulated industries and how to browse existing warning letters on the FDA website.
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
Introduction Reconciliation and Literature Review and Signal Detection in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
A brief introduction on medical device , how iit is regulated in india,its marketing authorization,classification, notified devices,import of device and registration process, fnctions of medical device department.
Module 01 Introduction To FdA and Quality System RegulationQACATX
The document provides an overview of the history and development of regulations by the U.S. Food and Drug Administration (FDA). It discusses the origins of the FDA in the late 19th/early 20th century in response to concerns about food and drug safety. Major milestones include the 1906 Pure Food and Drug Act, the 1938 Federal Food, Drug, and Cosmetic Act, and the 1976 Medical Device Amendments. The Quality System Regulation of 1996 refined Good Manufacturing Practice standards and emphasized design controls to ensure medical devices and manufacturers meet FDA requirements for safety and effectiveness. The regulation establishes requirements in several areas including management responsibility, design controls, purchasing, corrective actions, and distribution that medical device manufacturers must comply with.
This document is the annual report on Form 10-K filed by iTeos Therapeutics, Inc. with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2021. The report provides information on iTeos' business operations, financial results, subsidiaries, legal proceedings, executive officers, directors and auditors. It also includes iTeos' audited financial statements.
The document discusses Sri Lanka's transition to International Financial Reporting Standards (IFRS). It provides an overview of SLFRS and LKAS accounting standards. It outlines the diagnostic stage for assisting companies transitioning to SLFRS, including the transition date, comparative period, and reporting period. Disclosure requirements under SLFRS are also summarized such as the minimum content required for financial statements and notes.
This document discusses the accounting communication process and the key players involved. It provides an overview of:
- The roles of management, independent auditors, information intermediaries, government regulators, and financial statement users in the accounting communication process.
- The disclosure process companies go through, including issuing press releases, annual reports, quarterly reports, and SEC filings.
- Formats for the income statement, balance sheet, and cash flow statement that are included in annual and quarterly reports.
- International differences in accounting standards between US GAAP and IFRS.
The document is intended to help readers understand the people and reports involved in ensuring the integrity of financial information that is communicated.
INTRODUCTIONAnnual Report Analysis Projectis designed to get y.docxBHANU281672
INTRODUCTION
Annual Report Analysis Project
is designed to get you familiar with a real company’s financial statements and disclosures. The purpose of the project is for student to be able to identify the MANDATORY AND VOLUNTARY disclosure of financial information rules.
REQUIREMENT
Form into a group of 2 students.
Choose
two companies in the same business and industry
that are listed on Tadawul stock market.
Go to
www.tadawul.com.sa
then click on
equities,
then click on
listed companies web link
. The list of companies with their official website is listed on the page.
Go to the company’s website to get each company’s
annual report for 2015 (the latest annual report)
All of the financial and company information that you need will be in the company’s Annual Report. Submit
soft copy of the annual reports
together with your written report.
Answer all of the questions to the best of your ability, using all of the accounting skills that you have accumulated in ACCT 110, 211, 314, AND 321 to answer the questions
You must submit your final report about your findings.
BACKGROUND INFORMATION
In Saudi Arabia, company need to follow the listing rules set by Capital market authority on financial information disclosure requirement. CMA listing rules article 42 details the disclosure of financial information and article 43 details the content of directors report (
www.cma.org.sa
).
PART A
Go to CMA website to find information about mandatory and voluntary disclosure of financial information that is requires by CMA of all the company listed on TADAWUL. Be specific on the disclosure requirement. Write a report on mandatory and voluntary disclosure.
PART B
Article 43 stated that annual report should include a review of operations and all of relevant factors affecting the company’s business which an investor requires to assess the assets, liabilities and financial position. The report should include:
1.
a description of the principal activities of the issuer and its subsidiaries. Be specific on
which page of the annual report
the information is recorded.
2.
a description of the issuer’s significant plans and decisions (including any restructuring, business expansion or discontinuance of operations of the issuer), the future prospects of the issuer’s business and any risks facing the issuer. Be specific on
which page of the annual report
the information is recorded.
3.
a summary, in the form of a table or a chart, of the assets and liabilities of the issuer and of the issuer’s business results for the
last five financial years
or from incorporation, whichever is shorter;
4.
a
geographical analysis
of the issuer’s gross revenues and its subsidiaries;
5.
an
explanation for any material differences
in the operating results of the previous year or any announced forecast made by the issuer;
6.
an explanation for any departure (not follow) from the accounting standards issued by SOCPA;
7.
Detail explanation about
...
Knowledge level icab class lectures
Knowledge level icab class lectures
Knowledge level icab class lectures
Knowledge level icab class lectures
Knowledge level icab class lectures
Based on the facts provided:
- ABUGIDA plc incurred losses in 2018 but is projecting profits in the coming years due to expected favorable changes in government policies.
- The owners have arranged additional financing to support the entity's expansion plans and working capital needs for the next 12 months.
- While the current liabilities exceed current assets, alternative financing has been arranged indicating the entity will be able to meet its short-term obligations.
Therefore, it appears ABUGIDA plc has adequate resources to continue as a going concern for the foreseeable future. As such, the financial statements should be prepared applying the going concern assumption.
The document provides a list of preliminary information requirements for conducting due diligence on a company. It requests information across 11 categories: [1] Overview, [2] Financial Statements, [3] Income Statement, [4] Customers, [5] Costs and Expenses, [6] Balance Sheet, [7] Cash Flow Statements, [8] Contingent Liabilities, [9] Related Parties, [10] Personnel, and [11] Taxation. The information requested includes organizational structure, financial statements, revenue and cost details, customer and supplier information, personnel details, taxation records, and other operational and legal documents.
This document is JFrog's annual report on Form 10-K filed with the SEC. It provides an overview of JFrog's business, including that JFrog provides a DevOps platform to enable organizations to continuously deliver software updates. In 2021, JFrog generated $206.7 million in revenue and had over 6,650 customers adopting its platform. The report discusses trends in software development and digital transformation that are increasing demand for DevOps solutions. It also contains the standard sections required in an annual report such as business overview, risk factors, financial statements, and corporate governance disclosures.
This document outlines the components and types of disclosures required under disclosure based regulation in India. It discusses initial and continuous disclosures that must be provided by public companies to shareholders, stock exchanges, and regulators. These include financial reports, details on board composition, related party transactions, risk management procedures, and certifications from CEOs and CFOs on internal controls and financial reporting. The goal of these extensive disclosure requirements is to promote transparency and investor protection.
The document provides an overview of eXtensible Business Reporting Language (XBRL), including what it is, how it works, key terms, SEC filing requirements, best practices for creating XBRL documents, and the process and deliverables for outsourcing XBRL services. XBRL creates machine-readable tags for financial disclosures to facilitate analysis and reuse of data. It requires tagging individual items in statements like the income statement, balance sheet, and cash flow statement according to established standards.
The document provides an overview of eXtensible Business Reporting Language (XBRL), including what it is, how it works, key terms, SEC filing requirements, best practices for tagging financial documents in XBRL format, and the process and deliverables for outsourcing XBRL filing services. XBRL creates standardized, machine-readable tags for financial disclosures to facilitate analysis and reuse of reported information. Companies must file various financial reports in XBRL format according to SEC phase-in schedules.
The document summarizes key changes and amendments related to the Companies Act 2013 between March and April 2021. Some important changes include amendments to Schedule III regarding additional disclosures for borrowings, investments, loans to related parties, crypto currency transactions etc. The Companies (Audit and Auditors) Amendment Rules 2021 require auditors to check for audit trails in accounting software. The CSR rules were also amended to allow research on COVID-19 vaccines as CSR spend and to define implementing agencies for CSR activities.
The document discusses accounting standards in India. It defines accounting standards and explains that the Institute of Chartered Accountants of India (ICAI) established the Accounting Standards Board to develop such standards. It then lists some key Indian Accounting Standards (AS) such as AS-2 on inventories, AS-3 on cash flow statements, and AS-9 on revenue recognition. The document also outlines the procedure for issuing accounting standards in India and concludes that standards promote transparent financial reporting and investor confidence.
Corporate reporting involves the disclosure of financial and non-financial information about a company to various stakeholders. It includes integrated reporting, financial reporting, corporate governance reporting, executive remuneration reporting, corporate social responsibility reporting, and narrative reporting. In India, the legal framework for corporate reporting includes requirements from the Companies Act and SEBI. Listed companies must comply with disclosure norms on financial statements, board composition, shareholder relations, and other matters. The objectives of corporate reporting are to provide useful information to investors and other users to make informed decisions.
This document provides information on applicable Indian accounting standards for different levels of enterprises and lists the various Indian Accounting Standards (AS) and International Accounting Standards (IAS). It discusses in detail AS 1 on disclosure of accounting policies, AS 2 on valuation of inventories, AS 5 on net profit/loss, prior period items and changes in accounting policies, AS 6 on depreciation, AS 9 on revenue recognition, and AS 26 on intangible assets. The key highlights include definitions, recognition and measurement principles, and disclosure requirements for these standards.
William blair-35th-annual-growth-stock-conferenceQuintiles2014
- Quintiles provides forward-looking statements and non-GAAP financial measures in this presentation. Actual results may differ materially from expectations due to various risk factors.
- The presentation discusses Quintiles' leadership in bio-pharma services, differentiated offerings and customer relationships, and consistent financial performance and profitable growth.
- Quintiles operates in an attractive and growing market for product development and integrated healthcare services, with increasing demand for outsourcing driving estimated 6-8% annual market growth through 2017.
Advanced Emissions Solutions presented at the Sidoti & Company Spring 2018 Conference on March 29, 2018. The presentation summarized AES's refined coal and emissions control businesses. It noted that the refined coal business is expected to generate $65-75 million in annual cash flows through 2021. It also discussed AES's priorities of increasing cash flows, evaluating opportunities to monetize tax assets or build on its public platform, and continuing to return capital to shareholders.
Similar to M&A Due Diligence List Pharma Biotech December 2022.pptx (20)
Structural Design Process: Step-by-Step Guide for BuildingsChandresh Chudasama
The structural design process is explained: Follow our step-by-step guide to understand building design intricacies and ensure structural integrity. Learn how to build wonderful buildings with the help of our detailed information. Learn how to create structures with durability and reliability and also gain insights on ways of managing structures.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.